ALPMY News and Press, Astellas Pharma Inc. ADR From 02/10/20

BOTHELL, Wash. and TOKYO , Feb. 10, 2020 /PRNewswire/ --  Seattle Genetics, Inc.  (Nasdaq: SGEN) and Astellas Pharma Inc.  (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced updated results from the phase 1b /2 clinical trial EV-103 in p...

Amgen   (NASDAQ: AMGN) beat Wall Street's earnings estimate with its fourth-quarter results. But the big biotech's 2020 outlook underwhelmed. Amgen expects to deliver modest earnings growth and return to revenue growth, but it wasn't enough to impress investors. During Amgen's quarterly...

TOKYO and SAN FRANCISCO , Jan. 30, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno , "FibroGen") today announced the submission of a supplemental New Drug Appli...

Quick Take Aditx Therapeutics ( ADTX ) has filed to raise $10.5 million in an IPO of its common stock and warrants, according to an S-1 registration statement . The company is a pre-clinical developer of immune suppression drugs to assist in organ transplantation procedures. ADTX is sti...

TOKYO and SAN FRANCISCO , Jan. 15, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and Chief Executive Officer: Kenji Yasukawa , Ph.D., "Astellas") today announced that it has successfully completed the previously announced acquisition of Audentes Therapeutics, Inc. ("...

After the company announced that Japanese biopharma Astellas (OTC: ALPMY) is licensing its technology, shares in Adaptimmune Therapeutics (NASDAQ: ADAP) are rallying 11.4% at 1:45 EST on Tuesday. Astellas will work with Adaptimmune to develop T-cell receptors (TCRs), chimeric ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Banks are making the biggest round of job cuts in four years as they slash costs to deal with a slow...

Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) acquires Xyphos, gaining the proprietary Advanced Cellular Control through Engineered Ligands (ACCEL) platform to develop new ways to direct immune cells to find, modulate, and destroy targeted cells throughout the body. More news on: Astel...

TOKYO and SOUTH SAN FRANCISCO, Calif. , Dec. 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Xyphos Biosciences, Inc. (CEO: James Knighton , "Xyphos") today announced that Astellas has acquired Xyphos....

TOKYO and BOTHELL, Wash. , Dec. 18, 2019 /PRNewswire/ --  Astellas Pharma Inc.   (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc.   (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) granted ...